Michele MBA - Galapagos Head Commercial
| GLPG Stock | USD 27.82 0.36 1.31% |
Executive
Michele MBA is Head Commercial of Galapagos NV ADR
| Age | 51 |
| Address | Generaal De Wittelaan L11 A3, Mechelen, Belgium, 2800 |
| Phone | 32 1 534 29 00 |
| Web | https://www.glpg.com |
Galapagos Management Efficiency
The company has return on total asset (ROA) of (0.0138) % which means that it has lost $0.0138 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0113 %, meaning that it created $0.0113 on every $100 dollars invested by stockholders. Galapagos' management efficiency ratios could be used to measure how well Galapagos manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Galapagos' Return On Equity is most likely to increase slightly in the upcoming years. At this time, Galapagos' Total Current Assets are most likely to increase significantly in the upcoming years. The Galapagos' current Intangible Assets is estimated to increase to about 134.3 M, while Intangibles To Total Assets are projected to decrease to 0.04.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Chau MBA | CytomX Therapeutics | N/A | |
| Anuj MD | Assembly Biosciences | N/A | |
| Lee Stern | Achilles Therapeutics PLC | N/A | |
| Sebastien Maloveste | NextCure | N/A | |
| Danielle OlanderMoghadassian | CytomX Therapeutics | N/A | |
| Daniel Hood | Achilles Therapeutics PLC | N/A | |
| Tamara LLM | Spero Therapeutics | 62 | |
| Colleen Sjogren | Nuvation Bio | N/A | |
| Jeanette Bjorkquist | Assembly Biosciences | N/A | |
| Stacy Rollinger | NextCure | N/A | |
| Marcia Belvin | CytomX Therapeutics | N/A | |
| Edward Samuel | Achilles Therapeutics PLC | N/A | |
| Steven CPA | NextCure | 61 | |
| Richard Colonno | Assembly Biosciences | 74 | |
| James Taylor | Achilles Therapeutics PLC | 63 | |
| YuWaye MD | CytomX Therapeutics | 55 | |
| Dawn Benson | CytomX Therapeutics | N/A | |
| Robert MBBS | Instil Bio | N/A | |
| Thomas Rollins | Assembly Biosciences | 68 | |
| Tariq Ahmed | Achilles Therapeutics PLC | N/A | |
| Moses Makunje | Nuvation Bio | 45 | |
Management Performance
| Return On Equity | 0.0113 | ||||
| Return On Asset | -0.0138 |
Galapagos NV ADR Leadership Team
Elected by the shareholders, the Galapagos' board of directors comprises two types of representatives: Galapagos inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Galapagos. The board's role is to monitor Galapagos' management team and ensure that shareholders' interests are well served. Galapagos' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Galapagos' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Andre Hoekema, Sr. VP of Corporate Devel. | ||
| John Montana, Managing Argenta | ||
| Walid AbiSaab, Member of the Executive Committee, Chief Medical Officer | ||
| Marieke Vermeersch, Head Communication | ||
| Ellen Aar, Head Development | ||
| Dirk Naeyer, Head Operations | ||
| Annelies Missotten, Executive Officer | ||
| Alice Dietrich, Head Affairs | ||
| Philippe Alen, Senior Development | ||
| Elizabeth Goodwin, VP Corporate Communications & Investor Relations | ||
| Michele MBA, Head Commercial | ||
| Chantal Tasset, Head Devel | ||
| Thad Huston, CFO COO | ||
| Sofie Gijsel, Head Relations | ||
| MBA MBA, COO Pres | ||
| Valeria Cnossen, Executive Counsel | ||
| PharmD Raboisson, Head VP |
Galapagos Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Galapagos a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0113 | ||||
| Return On Asset | -0.0138 | ||||
| Profit Margin | 1.14 % | ||||
| Operating Margin | (0.53) % | ||||
| Current Valuation | (1.72 B) | ||||
| Shares Outstanding | 65.9 M | ||||
| Shares Owned By Institutions | 31.72 % | ||||
| Number Of Shares Shorted | 1.57 M | ||||
| Price To Earning | (15.60) X | ||||
| Price To Book | 0.66 X |
Currently Active Assets on Macroaxis
When determining whether Galapagos NV ADR is a strong investment it is important to analyze Galapagos' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Galapagos' future performance. For an informed investment choice regarding Galapagos Stock, refer to the following important reports:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Galapagos NV ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. You can also try the Stocks Directory module to find actively traded stocks across global markets.
Complementary Tools for Galapagos Stock analysis
When running Galapagos' price analysis, check to measure Galapagos' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Galapagos is operating at the current time. Most of Galapagos' value examination focuses on studying past and present price action to predict the probability of Galapagos' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Galapagos' price. Additionally, you may evaluate how the addition of Galapagos to your portfolios can decrease your overall portfolio volatility.
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins |
Is Galapagos' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Galapagos. If investors know Galapagos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Galapagos listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 2.914 | Earnings Share 0.51 | Revenue Per Share 0.1852 | Quarterly Revenue Growth 0.066 | Return On Assets (0.01) |
The market value of Galapagos NV ADR is measured differently than its book value, which is the value of Galapagos that is recorded on the company's balance sheet. Investors also form their own opinion of Galapagos' value that differs from its market value or its book value, called intrinsic value, which is Galapagos' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Galapagos' market value can be influenced by many factors that don't directly affect Galapagos' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Galapagos' value and its price as these two are different measures arrived at by different means. Investors typically determine if Galapagos is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Galapagos' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.